Britannia Life Sciences Inc.
BLSIF
$0.04
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -50.17% | -64.06% | -72.80% | -49.34% | -46.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -50.17% | -64.06% | -72.80% | -49.34% | -46.63% |
| Cost of Revenue | 24.09% | -26.99% | -50.41% | -62.56% | -64.14% |
| Gross Profit | -28.13% | -58.38% | -70.51% | -76.66% | -72.61% |
| SG&A Expenses | 15.28% | -32.97% | -40.80% | -52.90% | -48.43% |
| Depreciation & Amortization | 5.07% | 108.41% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.81% | -48.53% | -56.12% | -33.43% | -29.16% |
| Operating Income | -606.90% | -313.24% | -153.96% | -129.71% | -110.83% |
| Income Before Tax | 42.81% | -665.62% | -255.53% | -220.83% | -210.66% |
| Income Tax Expenses | 19.13% | -68.63% | -82.44% | 5.06% | -35.79% |
| Earnings from Continuing Operations | 41.27% | -1,262.19% | -304.93% | -227.55% | -218.70% |
| Earnings from Discontinued Operations | -- | 45.37% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -249.75% | -242.82% | -557.32% | -19.78% | 104.88% |
| Net Income | 83.43% | 63.08% | 57.23% | -566.69% | -751.27% |
| EBIT | -606.90% | -313.24% | -153.96% | -129.71% | -110.83% |
| EBITDA | -1,580.59% | -233.99% | -142.74% | -120.87% | -103.80% |
| EPS Basic | 81.68% | 60.57% | 54.59% | -565.38% | -740.38% |
| Normalized Basic EPS | -25.35% | -12,300.00% | -426.92% | -486.36% | -343.75% |
| EPS Diluted | 81.68% | 60.57% | 54.59% | -565.38% | -740.38% |
| Normalized Diluted EPS | -25.35% | -12,300.00% | -426.92% | -486.36% | -343.75% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.01% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |